Overview
I first became interested in clinical immunology as a medical student studying autoimmune inflammatory eye disease at the National Institutes of Health. Since then, I have been inspired to understand what causes autoimmunity and immune deficiency disorders in order to improve the quality of life for my patients. I see patients with multiple complex immune disorders with particular expertise in autoimmune and Rheumatoid arthritis, primary Sjogren's syndrome, and the immunodeficiency disorders Common Variable Immunodeficiency (CVID), Adenosine Deaminase Deficiency (ADA) disorders, and WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis). My research investigates immune targets that may impact either the development of immune disease or identify new therapies for patients. The goal is to help us understand why and how immunologic diseases develop so that we may better treat them.
Current Duke Appointments & Affiliations
Recent News Items
View All News Items
Recent Scholarly Works
ADA2 genotype and enzyme activity may predict vasculitic or hematologic DADA2 phenotype.
Journal article J Hum Immun · September 7, 2026 Deficiency of adenosine deaminase 2 (DADA2) is an autoinflammatory disease with diverse phenotypes. We describe the genetics, phenotypes, and treatment of n = 48 DADA2 patients from Germany, Austria, and Switzerland. We report a high incidence of hematolog ... Full text Link to item CiteA case of progressive multifocal leukoencephalopathy in an adult patient with ADA-SCID.
Journal article J Hum Immun · September 7, 2026 This case report describes progressive multifocal leukoencephalopathy in a patient with ADA-SCID status after gene therapy. Persistent metabolic dysfunction likely contributed to JC virus reactivation, highlighting this rare complication of ADA-SCID and in ... Full text Link to item CiteReassessing AXP depletion due to inherited deficiency of adenosine deaminase 1.
Journal article J Allergy Clin Immunol · April 2026 Full text Link to item CiteRecent Grants
DAZ-304: A Long-term Extension Study of Dazodalibep in Participants with SS
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2025 - 2030A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infec
Clinical TrialPrincipal Investigator · Awarded by X4 Pharmaceuticals · 2025 - 2029RC18G007 Vor BioPharma -A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants with Active Primary Sjoegren's Disease
Clinical TrialPrincipal Investigator · Awarded by Vor Biopharma Inc. · 2026 - 2029View All Grants